Skip to main content
Reimbursement strategy

Cost-effective market access strategy for medical technologies in Europe

A holistic approach to reimbursement strategies trusted by global market leaders and SMEs

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Regular update of the List of reimbursable devices and Nominative Lists in Belgium

07 Jul 2023

On June 8, 2023, Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV) published an updated List of reimbursable devices and Nominative Lists of brands to come into force on July 1, 2023.

Three new material codes concerning cardiovascular and spinal procedures with the corresponding conditions were added to the List of reimbursable devices. An example of a new code is 184214 - 184225 “Biological valve made from animal pericardium with proven reduced calcification of the valve leaflets, implanted in the aortic position”.

Several new branded devices were registered on the Nominative Lists connected to new and already existing material codes.

See more information in French here and Dutch here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.